Sector: Healthcare Services - Healthcare
BSE Code: 536565
NSE Symbol: NOVELIX
ISIN: INE314I01036
📈 Novelix Pharmaceuticals Issues 1.15M Shares via Warrant Conversion • Allotted 1,150,000 equity shares at ₹20 each (₹10 face value + ₹10 premium) • Shares issued upon conversion of warrants from January 10, 2025 preferential allotment • Total subscription amount received: ₹1.725 crore (75% of is…
📈 Board Update: Director Resigns at Novelix Pharmaceuticals - Mr. Jivamohan Divakar Valluri resigned as Non-Executive Non-Independent Director - Resignation effective close of business hours on March 30, 2026 - Reason cited: pre-occupation and other personal commitments - Also stepped down from A…
🔁 Novelix Pharma Board Reforms Key Committees • Board of Directors meeting held on March 30, 2026, at registered office in Hyderabad. • Reconstituted Audit Committee: Janardhan Das Kabra (Chairperson, Independent), Mayuri Baidya (Member, Independent), Sridevi Belide (Member, Non-Independent). • R…
📈 Novelix Pharma Expands Capital Base with Warrant Conversion • Allotted 1,150,000 equity shares at ₹20 each (₹10 face value + ₹10 premium) • Total conversion amount: ₹1,72,50,000 • Major allottees: SRINIDHI FINE-CHEMICALS LLP (1,100,000 shares) and NARAHARI BELIDE (50,000 shares) • Paid-up equit…
📈 Mallela Venkataramna Reddy Boosts Stake in Novelix Pharmaceuticals - Mallela Venkataramna Reddy acquired 330,000 equity shares via preferential allotment on February 12, 2026. - Post-acquisition, his total holding stands at 1,830,000 shares, representing 9.18% of voting rights and 6.71% of dilu…
📈 Key Insider Boosts Stake in Novelix Pharmaceuticals - Vupparapalli Pavani, a promoter group member, was allotted 325,000 equity shares on February 12, 2026. - Total shareholding rose from 400,000 to 725,000 shares post-allotment. - Voting rights increased from 2.27% to 3.64% (on a total capital…
📈 Mallela Venkataramna Reddy Increases Stake in Novelix Pharmaceuticals to 9.18% • Acquired 330,000 equity shares via preferential allotment on February 12, 2026 • Represents 1.66% of total share capital and 1.21% of diluted voting capital • Total holding now stands at 1,830,000 shares (9.18% of …
📈 Vupparapalli Pavani Increases Stake in Novelix Pharmaceuticals • Vupparapalli Pavani, a promoter, acquired 325,000 equity shares via preferential allotment on February 12, 2026 • Her shareholding increased from 400,000 shares (2.27% of voting capital) to 725,000 shares (3.64% of voting capital)…
📊 Novelix Pharmaceuticals Revises Q3 FY2025 Results After Typo Correction - Total income for Q3 (ended Dec 31, 2025): ₹4,840.27 lakhs - Net profit after tax: ₹100.44 lakhs - Earnings per share (EPS): basic ₹0.58 and diluted ₹0.85 for continuing operations - Revised results approved by the Board o…
📊 Novelix Pharmaceuticals Reports No Fund Usage Deviations in Q3 FY2026 - Raised ₹231.75 lakhs on August 14, 2025 - Raised ₹249.15 lakhs on October 23, 2025 - Raised ₹161.1 lakhs on December 24, 2025 - No deviation or variation in the use of funds reported - All funds fully utilized for long-term…
📈 Novelix Pharma Raises ₹13.92 Cr via Preferential Issue • Issued 23,20,000 equity shares at ₹60 each (face value ₹10, premium ₹50). • Total funds raised: ₹13,92,00,000 (Thirteen Crore Ninety-Two Lakhs). • Shares allotted to 36 investors, including promoter group and non-promoters. • Key allottee…
📈 Novelix Pharmaceuticals Q3 FY2026: Revenue Soars to ₹4840.27 Lakhs • Total income for Q3 FY2026: ₹4,840.27 lakhs (vs. ₹530.09 lakhs in Q3 FY2025) • Net profit after tax for Q3 FY2026: ₹100.44 lakhs (vs. ₹14.79 lakhs in Q3 FY2025) • 9-month total income: ₹10,714.52 lakhs (vs. loss of ₹7.65 lakhs…
📊 Novelix Pharma Q3 FY26 Results: ₹4,840.27 Lakh Revenue with ₹100.44 Lakh Net Profit • Total income of ₹4,840.27 lakh for Q3 FY26 (quarter ended Dec 31, 2025) • Net profit of ₹100.44 lakh for Q3 FY26 • Allotted 23,20,000 equity shares via preferential issue at ₹60 per share, raising ₹13.92 crore…
📊 Novelix Pharma Q3 FY26 Results Board Meeting Scheduled - Board meeting scheduled for February 12, 2026 to discuss unaudited standalone financial results for Q3 ending December 31, 2025 - Approval of equity shares allotment through preferential basis to be considered - Trading window closed for …
Novelix Pharma Allots 400K Shares to Strategic Investors 💼📈 - 400,000 equity shares allotted at ₹20 each (₹10 face value + ₹10 premium). - Warrants converted from a preferential issue approved by shareholders on November 18, 2024. - Total funds received: ₹60,00,000 (75% of issue price) for 400K …
Novelix Pharma Allots 400K Shares at ₹20 Each 🏦 - 400,000 equity shares allotted at ₹20 each (₹10 face value + ₹10 premium). - Warrants converted as part of earlier preferential issue; 7,265,000 warrants already converted prior. - Three non-promoter allottees: Arpan Vipin Mantri (200,000 shares),…
🚀 Novelix Pharma Welcomes New Non-Executive Director: Ms. Sridevi Belide - Ms. Sridevi Belide appointed as Non-Executive Non-Independent Director, approved by shareholders on 09th January, 2026. - Effective from 23rd October, 2025. - Holds an MBBS degree, adding healthcare & scientific expertise …
📢 New Leadership at Novelix Pharmaceuticals: Ms. Sridevi Belide Joins Board - Ms. Sridevi Belide (DIN: 10455373) appointed as Non-Executive Non-Independent Director. - Shareholders approved the appointment in an Extra Ordinary General Meeting on 09th January, 2026. - Effective from 23rd October, …
Novelix Pharma EGM Results: Key Decisions & Voting Breakdown 📊 - Held Extraordinary General Meeting (EGM) on January 09, 2026 via video conferencing. - Total shareholders as of cutoff date (Jan 2, 2026): 3,085. - 3 Promoters and 61 Public shareholders attended virtually. - Resolution 1: Equity sh…
Novelix Pharma EGM Recap: Key Decisions & Voting Results Coming Soon 📊 - EGM held on 09 Jan 2026 via video conferencing with 64 attendees. - Two agenda items: Preferential equity shares (Special Resolution) and confirmation of Ms. Sridevi Belide as Non-Executive Director (Ordinary Resolution). - …